menu

CME: Are You Failing Your HCT Recipients? A Case Study on CMV Prophylaxis

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Are You Failing Your HCT Recipients? A Case Study on CMV Prophylaxis

close
0.25 credits
15 Minutes
Are You Failing Your HCT Recipients? A Case Study on CMV Prophylaxis
Restart
Resume
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
Details
Presenters
Related
Comments
  • Overview

    Infection with cytomegalovirus (CMV) is a source of high morbidity and preventable mortality in hematopoietic stem cell transplant (HCT) recipients, and the risk of CMV reactivation is significant in allogeneic HSCT recipients. Fortunately, a new era of therapy has emerged, marked by the development of targeted treatments showing stronger efficacy over more traditional antiviral therapies. But what does the application of those therapies look like in action?

    This activity will review the appropriate CMV pre-emptive therapy in patients undergoing HSCT as well as discuss the newer approaches to preventing CMV infection and how clinical practice guidelines and expert recommendations have changed regarding the role of prophylaxis in CMV seropositive recipients.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Roy F. Chemaly, MD, MPH, FIDSA, FACP
    Professor of Medicine
    UT MD Anderson Cancer Center
    Houston, TX 

    Consulting Fees: Chimerix, Inc., Clinigen, Merck, Oxford Immunotec, Shire
    Contracted Research: Chimerix, Merck, Oxford Immunotec, Shire

    Miguel-Angel Perales, MD
    Deputy Chief, Adult Bone Marrow Transplantation Service
    Memorial Sloan Kettering Cancer Center
    New York, NY 

    Consulting Fees: Abbvie, Bellicum, Celgene, Bristol-Myers Squibb, Incyte, Merck, Novartis, Nektar Therapeutics, Omeros, Takeda
    Member, DSMB: Cidara Therapeutics, Medigene, Servier

    Reviewers/Content Planners/Authors:

    • Ann Early has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Nick Lombardi has ownership interest with Vertex Pharmaceuticals.
    • Brian P. McDonough, MD, FAAFP has nothing to disclose.
    • William Mencia, MD, FACEHP, CHCP has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Select appropriate CMV pre-emptive therapy in patients undergoing HSCT based on patient specific factors.
    • Explain how clinical practice guidelines and expert recommendations have changed regarding the role of prophylaxis in CMV seropositive recipients.
  • Target Audience

    This activity is designed to meet the educational needs of hematologists/oncologists.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education, designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from Merck.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Infection with cytomegalovirus (CMV) is a source of high morbidity and preventable mortality in hematopoietic stem cell transplant (HCT) recipients, and the risk of CMV reactivation is significant in allogeneic HSCT recipients. Fortunately, a new era of therapy has emerged, marked by the development of targeted treatments showing stronger efficacy over more traditional antiviral therapies. But what does the application of those therapies look like in action?

    This activity will review the appropriate CMV pre-emptive therapy in patients undergoing HSCT as well as discuss the newer approaches to preventing CMV infection and how clinical practice guidelines and expert recommendations have changed regarding the role of prophylaxis in CMV seropositive recipients.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Roy F. Chemaly, MD, MPH, FIDSA, FACP
    Professor of Medicine
    UT MD Anderson Cancer Center
    Houston, TX 

    Consulting Fees: Chimerix, Inc., Clinigen, Merck, Oxford Immunotec, Shire
    Contracted Research: Chimerix, Merck, Oxford Immunotec, Shire

    Miguel-Angel Perales, MD
    Deputy Chief, Adult Bone Marrow Transplantation Service
    Memorial Sloan Kettering Cancer Center
    New York, NY 

    Consulting Fees: Abbvie, Bellicum, Celgene, Bristol-Myers Squibb, Incyte, Merck, Novartis, Nektar Therapeutics, Omeros, Takeda
    Member, DSMB: Cidara Therapeutics, Medigene, Servier

    Reviewers/Content Planners/Authors:

    • Ann Early has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Nick Lombardi has ownership interest with Vertex Pharmaceuticals.
    • Brian P. McDonough, MD, FAAFP has nothing to disclose.
    • William Mencia, MD, FACEHP, CHCP has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Select appropriate CMV pre-emptive therapy in patients undergoing HSCT based on patient specific factors.
    • Explain how clinical practice guidelines and expert recommendations have changed regarding the role of prophylaxis in CMV seropositive recipients.
  • Target Audience

    This activity is designed to meet the educational needs of hematologists/oncologists.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education, designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from Merck.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 3/31/20